TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19223284

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg once daily
Number of subjects: 23504

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg once daily
Number of subjects: 23504

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg OA cohort
Number of subjects: 23504

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg OA cohort
Number of subjects: 23504

Group type: EXPERIMENTAL
Intervention: Etoricoxib RA cohort
Number of subjects: 23504

Group type: COMPARATOR
Intervention: Diclofenac 75 mg twice daily
Number of subjects: 23504
Study: 16510058

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive therapies
Number of subjects: 0
Study: 15120553

Group type: EXPERIMENTAL
Intervention: Learning of new names
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cortical learning effect
Number of subjects: 5
Study: 11739476

Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin (5.0 pmol/kg/min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 9
Study: 9351694

Group type: EXPERIMENTAL
Intervention: 15 weeks of training involving both continuous and interval ergocycle exercise sessions
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (13 subjects: 5 women and 8 men)
Number of subjects: 36
Study: 8243076

Group type: EXPERIMENTAL
Intervention: Nonlinear 'black box' NARMAX identification package
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured two‐compartment Belville model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled gas mixture
Number of subjects: 0
Study: 2435738

Group type: EXPERIMENTAL
Intervention: Intra-arterial prostacyclin infusion
Number of subjects: 29

Group type: COMPARATOR
Intervention: Praxilene (naftidrofuryl oxalate)
Number of subjects: 29
Study: 29644962

Group type: EXPERIMENTAL
Intervention: Curcumin (400 mg/kg)
Number of subjects: 540
Study: 28314746

Group type: EXPERIMENTAL
Intervention: Community-level hygiene education program and water quality intervention using riverbank filtration technology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riverbank filtration-treated water
Number of subjects: 0
Study: 25212409

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (30 mg oral)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22134736

Group type: EXPERIMENTAL
Intervention: Subcutaneous closed-suction drainage
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional closed-suction drainage
Number of subjects: 105
Study: 21226544

Group type: EXPERIMENTAL
Intervention: Exercise intervention for six weeks
Number of subjects: 209

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 209
Study: 18505083

Group type: EXPERIMENTAL
Intervention: Supportive care plus MLT (20 mg/day, orally in the evening)
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: MLT plus SC low-dose IL-2 (3 MIU/day for 5 days/week, for 4 consecutive weeks)
Number of subjects: 846

Group type: COMPARATOR
Intervention: Best supportive care only
Number of subjects: 846
Study: 17179687

Group type: EXPERIMENTAL
Intervention: Bladder Training (BT)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Tolterodine (To, 2 mg twice daily)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Combination of Bladder Training and Tolterodine (Co)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 139
Study: 15249259

Group type: EXPERIMENTAL
Intervention: Group‐mediated cognitive behavioral physical activity intervention program (GMCB)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation program (CRP)
Number of subjects: 147
Study: 11423457

Group type: EXPERIMENTAL
Intervention: Phacoemulsification (Phako)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Extracapsular cataract extraction (ECCE)
Number of subjects: 476
Study: 9257199

Group type: EXPERIMENTAL
Intervention: Inspired oxygen concentration (FIO2) decreased from 21% to 10%
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FIO2 levels reduced to ranges of 95% to 90%, 89% to 85%, 84% to 80%, and 79% to 70%
Number of subjects: 16
Study: 8324274

Group type: EXPERIMENTAL
Intervention: 0.3% podophyllotoxin solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.3% podophyllotoxin cream
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.15% podophyllotoxin cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 3706190

Group type: EXPERIMENTAL
Intervention: 100 mg/day of pyridoxine X HCl
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 27863185

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 271

Group type: COMPARATOR
Intervention: Best practice care
Number of subjects: 271
Study: 26722670

Group type: EXPERIMENTAL
Intervention: Total urinary phthalate metabolites (free plus glucuronidated forms)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Free mono‐butyl phthalate (MBP)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Total mono‐butyl phthalate (MBP)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Free mono‐(2‐ethyl‐5‐carboxypentyl) phthalate (MECPP)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Total mono‐(2‐ethyl‐5‐carboxypentyl) phthalate (MECPP)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Mono‐ethyl phthalate (MEP)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Mono‐(2‐ethyl‐5‐oxohexyl) phthalate (MEOHP)
Number of subjects: 293
Study: 24419825

Group type: EXPERIMENTAL
Intervention: Functional brace for 3 weeks
Number of subjects: 186

Group type: COMPARATOR
Intervention: Walking boot with weight‐bearing allowed, pain management, ice, and elevation with restricted joint mobilization for 3 weeks
Number of subjects: 186
Study: 22803768

Group type: EXPERIMENTAL
Intervention: Monthly oral ibandronate 150 mg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 20382081

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 226
Study: 18535879

Group type: EXPERIMENTAL
Intervention: Technetium‐99m methoxyisobutylisonitrile (Tc‐99m MIBI) gated SPECT
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (healthy controls, 20 patients total, 12 men and 8 women)
Number of subjects: 23
Study: 11464714

Group type: EXPERIMENTAL
Intervention: Patients after stroke
Number of subjects: 56

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 56
Study: 9500801

Group type: EXPERIMENTAL
Intervention: Intralipid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intralipid/glucose mixture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 20
Study: 7875147

Group type: EXPERIMENTAL
Intervention: GM‐CSF (60 micrograms/m2) with antibiotics (ticarcillin‐clavulanate plus netilmicin)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: GM‐CSF with amphotericin B
Number of subjects: 91
Study: 3277154

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 47

Group type: COMPARATOR
Intervention: Griseofulvin
Number of subjects: 47
Study: 30711184

Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac (31.5 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Acetaminophen (1000 mg) and Ibuprofen (600 mg)
Number of subjects: 70
Study: 29125435

Group type: EXPERIMENTAL
Intervention: Intervention aimed at promoting CRC screening
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Sociodemographic and psychosocial variables
Number of subjects: 416
Study: 25647447

Group type: EXPERIMENTAL
Intervention: Network Support (NS)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Network Support+Contingency Management (NS+CM)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Case Management (CaseM)
Number of subjects: 210
Study: 22753402

Group type: EXPERIMENTAL
Intervention: FIN-RACo + Infliximab (INFL)
Number of subjects: 99

Group type: COMPARATOR
Intervention: FIN-RACo + Placebo (Pla)
Number of subjects: 99
Study: 21640958

Group type: EXPERIMENTAL
Intervention: Melody cues for titles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lyrics as a source of familiarity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulation of familiarity
Number of subjects: 0
Study: 18287441

Group type: EXPERIMENTAL
Intervention: Automated CO2 insufflation
Number of subjects: 74
Study: 16497281

Group type: EXPERIMENTAL
Intervention: Peripheral precue (140 ms) indicating the signal location with 80% validity.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Classification images technique used to estimate perceptual templates.
Number of subjects: 2
Study: 12889783

Group type: COMPARATOR
Intervention: 500‐mg clarithromycin tablet (Test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 500‐mg clarithromycin tablet (Reference formulation)
Number of subjects: 24
Study: 10861653

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 0
Study: 9378847

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg every 12 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8466017

Group type: EXPERIMENTAL
Intervention: Gentle massage of the epigastric area for 30 min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 16
Study: 31725787

Group type: EXPERIMENTAL
Intervention: Standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy
Number of subjects: 3300
Study: 30056104

Group type: EXPERIMENTAL
Intervention: Higher AHEI-2010 cumulative average score (reflecting long-term healthy diet quality)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: No or light alcohol consumption (component of AHEI-2010)
Number of subjects: 459
Study: 27622897

Group type: EXPERIMENTAL
Intervention: DA alginate antacid
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 24521295

Group type: EXPERIMENTAL
Intervention: Reflectance confocal microscopy (RCM)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Standardized skin surface biopsy (SSSB)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RCM
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RCM vs SSSB
Number of subjects: 48
Study: 23110157

Group type: EXPERIMENTAL
Intervention: Personalized feedback pamphlet
Number of subjects: 1767

Group type: COMPARATOR
Intervention: Control pamphlet
Number of subjects: 1767

Group type: COMPARATOR
Intervention: No intervention control
Number of subjects: 1767
Study: 20329658

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg (test product)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Exemestane 25 mg (reference product)
Number of subjects: 74
Study: 18446589

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 80/4.5 microg x 2 inhalations (160/9 microg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone/salmeterol DPI 250/50 microg x 1 inhalation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albuterol pMDI 90 microg x 2 inhalations (180 microg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo pMDI
Number of subjects: 0
Study: 16386890

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (CHART)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 402
Study: 12793220

Group type: EXPERIMENTAL
Intervention: Crest Professional Whitestrips (6.5% H2O2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Day White 2 (7.5% H2O2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nite White Excel 2 (16% carbamide peroxide equivalent)
Number of subjects: 90
Study: 10889800

Group type: EXPERIMENTAL
Intervention: Various interventions causing negative energy balance (specific interventions not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss as a treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: RCT design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-sample studies with regression analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine clinical practice treatments
Number of subjects: 0
Study: 8783687

Group type: EXPERIMENTAL
Intervention: 1 rejection treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2 rejection treatments
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: >= 3 rejection treatments
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Negative pretransplantation CMV serology
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Recipient-negative and donor-positive pretransplantation CMV serology
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CMV infection
Number of subjects: 15
Study: 1731541

Group type: EXPERIMENTAL
Intervention: 3 micrograms/mL buprenorphine with 0.015% bupivacaine and 1 microgram/mL epinephrine
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 3 micrograms/mL fentanyl with 0.015% bupivacaine and 1 microgram/mL epinephrine
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 3 micrograms/mL fentanyl with 0.015% bupivacaine
Number of subjects: 78
Study: 6475749

Group type: EXPERIMENTAL
Intervention: Positive Rose Questionnaire for myocardial infarction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive clinical history of myocardial infarction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive ECG for myocardial infarction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline prevalence of angina pectoris
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rose Questionnaire evidence of myocardial infarction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-year incidence of myocardial infarction, positive ECG or history, or positive Rose Questionnaire
Number of subjects: 0
Study: 30673028

Group type: EXPERIMENTAL
Intervention: SRP plus 3 watts gaseous ozone in two separate applications five days apart
Number of subjects: 40

Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 40
Study: 30442354

Group type: EXPERIMENTAL
Intervention: Cervical thrust manipulation
Number of subjects: 54
Study: 26423396

Group type: EXPERIMENTAL
Intervention: Remotely monitored (RM) pacemakers
Number of subjects: 76

Group type: COMPARATOR
Intervention: Hospital-monitored (HM) pacemakers
Number of subjects: 76
Study: 25205062

Group type: EXPERIMENTAL
Intervention: 3-0 V-Loc
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3-0 Stratafix
Number of subjects: 40
Study: 22188239

Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention (PFI)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention (CBI)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Assessment-Only Control (AOC)
Number of subjects: 147
Study: 19996349

Group type: EXPERIMENTAL
Intervention: Inhaled mannitol alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Nebulised rhDNase alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combination of mannitol and rhDNase
Number of subjects: 38
Study: 17645262

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture plus epidural analgesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 60
Study: 16083518

Group type: EXPERIMENTAL
Intervention: Zolmitriptan orally disintegrating tablet (ODT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zolmitriptan ODT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11788558

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human IL-10 (20 microg/kg) in patients with CACD
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human IL-10 (20 microg/kg) in patients with MCD
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo in patients with CACD
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo in patients with MCD
Number of subjects: 126
Study: 9797592

Group type: EXPERIMENTAL
Intervention: Cows' milk protein (n = 758)
Number of subjects: 1533

Group type: COMPARATOR
Intervention: Placebo (n = 775)
Number of subjects: 1533
Study: 7665750

Group type: EXPERIMENTAL
Intervention: Least squares fitting (LSF) method during pressure support ventilation (PSV)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Least squares fitting (LSF) method at increased pressure support levels
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Least squares fitting (LSF) method in controlled mechanical ventilation (CMV)
Number of subjects: 11
Study: 2576246

Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride (morning dosage)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride (evening dosage)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (morning and evening)
Number of subjects: 6
Study: 551922

Group type: EXPERIMENTAL
Intervention: Specific hypotensive therapy
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: No specific treatment
Number of subjects: 3

Group type: COMPARATOR
Intervention: Hospital sample
Number of subjects: 3
Study: 31520543

Group type: EXPERIMENTAL
Intervention: Probiotic lozenges
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control lozenges
Number of subjects: 39
Study: 30204517

Group type: EXPERIMENTAL
Intervention: Casein protein (CP) 40 g presleep
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON) 40 g carbohydrates presleep
Number of subjects: 10
Study: 28885372

Group type: EXPERIMENTAL
Intervention: Bright white light (10,000 lux; active condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dim red light (<300 lux; control condition)
Number of subjects: 0
Study: 26083409

Group type: EXPERIMENTAL
Intervention: Lipid-based nutritional supplement with additional vitamins and minerals
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (Lipid-based nutritional supplement without additional vitamins and minerals)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 181
Study: 22843632

Group type: EXPERIMENTAL
Intervention: UV photo intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No UV photo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No MI
Number of subjects: 0
Study: 21770996

Group type: EXPERIMENTAL
Intervention: SRP with azithromycin (AZM) 500 mg/day for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 40
Study: 19293261

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (5 or 10 g/d) plus GH (0, 3, or 5 microg/kg . d) for 16 weeks
Number of subjects: 122
Study: 16686554

Group type: EXPERIMENTAL
Intervention: Leucine and whey protein supplementation (SUPP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Carbohydrate placebo (PL)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 33
Study: 12918546

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atrial-synchronised biventricular pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan with ACE inhibitor and beta-blocker
Number of subjects: 0
Study: 11015817

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 227

Group type: COMPARATOR
Intervention: Conventional antipsychotic medications
Number of subjects: 227
Study: 8784894

Group type: EXPERIMENTAL
Intervention: Three-dimensional treatment planning
Number of subjects: 15

Group type: COMPARATOR
Intervention: Spared glands
Number of subjects: 15
Study: 1294196

Group type: EXPERIMENTAL
Intervention: Internal imagery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: External imagery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Actual exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Internal imagery and External imagery
Number of subjects: 30
Study: 6738652

Group type: EXPERIMENTAL
Intervention: Theophylline (mean plasma level, 13 +/- 2 mg per liter) after 7 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Theophylline after 30 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30539303

Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 86

Group type: COMPARATOR
Intervention: Non-tourniquet
Number of subjects: 86
Study: 31162568

Group type: EXPERIMENTAL
Intervention: Neladenoson 5 mg
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Neladenoson 10 mg
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Neladenoson 20 mg
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Neladenoson 30 mg
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Neladenoson 40 mg
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 28629329

Group type: EXPERIMENTAL
Intervention: Decision aids (DA)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Standard brochure
Number of subjects: 816
Study: 26049794

Group type: EXPERIMENTAL
Intervention: 1-minute rest interval (1RI)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 2-minute rest interval (2RI)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1RI
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 2RI
Number of subjects: 22
Study: 24483103

Group type: EXPERIMENTAL
Intervention: Self‐formulated decoctions for activating blood nourishing blood (ABNB), activating blood removing stasis (ABRS), and activating blood softening hard mass (ABSHM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Compound Biejia Ruangan Tablet (CBRT)
Number of subjects: 100
Study: 21593464

Group type: EXPERIMENTAL
Intervention: Steri-Strips patching
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Paper patching
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conservative observation
Number of subjects: 87
Study: 19231318

Group type: EXPERIMENTAL
Intervention: Dobutamine‐atropine stress echocardiography (DASE)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Electrocardiogram exercise testing (EET)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 290